Silymarin as a potential hypocholesterolaemic drug
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
9708694
Knihovny.cz E-zdroje
- MeSH
- anticholesteremika farmakologie MeSH
- biologická dostupnost MeSH
- inhibitory enzymů farmakologie MeSH
- játra fyziologie MeSH
- lidé MeSH
- lipidy krev MeSH
- lipoproteiny krev metabolismus MeSH
- metabolismus lipidů MeSH
- peroxidasy antagonisté a inhibitory MeSH
- silymarin farmakokinetika farmakologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- anticholesteremika MeSH
- inhibitory enzymů MeSH
- lipidy MeSH
- lipoproteiny MeSH
- peroxidasy MeSH
- silymarin MeSH
Silymarin, a mixture of flavonolignans from medicinal plant Silybum marianum, is used in supportive treatment of liver diseases of different etiology due to its hepatoprotective activity, which is considered to involve antioxidative and the membrane stabilizing effects. The liver plays an important role in regulation of metabolism of plasma lipoproteins, and liver injury is often reflected as a secondary dyslipoproteinaemia, which may lead to the development of atherosclerosis, particularly when associated with hypercholesterolaemia. This review summarizes the experimental evidence indicating that silymarin-induced protection of liver functions may be of benefit with regard to liver lipid metabolism related to the regulation of plasma lipoproteins. Moreover, some data suggest that silymarin could have a direct effect on liver cholesterol metabolism by inhibiting cholesterol biosynthesis. It is proposed that silymarin deserves to be studied as a potential hypocholesterolaemic agent.
Chirality Matters: Biological Activity of Optically Pure Silybin and Its Congeners
Biotransformation of Silymarin Flavonolignans by Human Fecal Microbiota